DE69733861D1 - Verwendung von neuronalem apoptose-inhibitorprotein - Google Patents

Verwendung von neuronalem apoptose-inhibitorprotein

Info

Publication number
DE69733861D1
DE69733861D1 DE69733861T DE69733861T DE69733861D1 DE 69733861 D1 DE69733861 D1 DE 69733861D1 DE 69733861 T DE69733861 T DE 69733861T DE 69733861 T DE69733861 T DE 69733861T DE 69733861 D1 DE69733861 D1 DE 69733861D1
Authority
DE
Germany
Prior art keywords
inhibitor protein
apoptosis inhibitor
neuronal apoptosis
naip
apoptosis
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69733861T
Other languages
English (en)
Other versions
DE69733861T2 (de
Inventor
G Korneluk
E Mackenzie
Natalie Roy
George Robertson
Katsu Tamai
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Ottawa
Original Assignee
University of Ottawa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Ottawa filed Critical University of Ottawa
Publication of DE69733861D1 publication Critical patent/DE69733861D1/de
Application granted granted Critical
Publication of DE69733861T2 publication Critical patent/DE69733861T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4747—Apoptosis related proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/105—Murine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2510/00—Detection of programmed cell death, i.e. apoptosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Analytical Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Toxicology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Pathology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physics & Mathematics (AREA)
  • Urology & Nephrology (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • General Physics & Mathematics (AREA)
  • Hospice & Palliative Care (AREA)
  • General Engineering & Computer Science (AREA)
  • Food Science & Technology (AREA)
  • Virology (AREA)
DE69733861T 1996-01-19 1997-01-17 Verwendung von neuronalem apoptose-inhibitorprotein Expired - Fee Related DE69733861T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB9601108.5A GB9601108D0 (en) 1996-01-19 1996-01-19 Neuronal apoptosis inhibitor protein (NAIP)
GB9601108 1996-01-19
PCT/IB1997/000142 WO1997026331A2 (en) 1996-01-19 1997-01-17 Use of neuronal apoptosis inhibitor protein (naip)

Publications (2)

Publication Number Publication Date
DE69733861D1 true DE69733861D1 (de) 2005-09-08
DE69733861T2 DE69733861T2 (de) 2006-05-24

Family

ID=10787268

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69733861T Expired - Fee Related DE69733861T2 (de) 1996-01-19 1997-01-17 Verwendung von neuronalem apoptose-inhibitorprotein

Country Status (11)

Country Link
US (2) US6994957B2 (de)
EP (2) EP1609864A3 (de)
JP (1) JP4005135B2 (de)
AT (1) ATE301192T1 (de)
AU (1) AU1614997A (de)
CA (1) CA2215793C (de)
DE (1) DE69733861T2 (de)
DK (1) DK0815231T3 (de)
ES (1) ES2245790T3 (de)
GB (1) GB9601108D0 (de)
WO (1) WO1997026331A2 (de)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6156535A (en) 1995-08-04 2000-12-05 University Of Ottawa Mammalian IAP gene family, primers, probes, and detection methods
GB9601108D0 (en) * 1996-01-19 1996-03-20 Univ Ottawa Neuronal apoptosis inhibitor protein (NAIP)
ATE398459T1 (de) * 1996-04-26 2008-07-15 Univ Ottawa Verwendung von naip oder iap für die behandlung und vorbeugung von neuronalen erkrankungen
US6133437A (en) 1997-02-13 2000-10-17 Apoptogen, Inc. Modulation of IAPs for the treatment of proliferative diseases
JPH11116599A (ja) * 1997-10-14 1999-04-27 Japan Science & Technology Corp アポトーシス抑制蛋白質とこの蛋白質をコードする 遺伝子およびそのｃＤＮＡ
US6171821B1 (en) 1998-07-24 2001-01-09 Apoptogen, Inc. XIAP IRES and uses thereof
JP2000125861A (ja) * 1998-10-26 2000-05-09 Japan Science & Technology Corp ヒト・アポトーシス抑制蛋白質ｎａｉｐに対する モノクローナル抗体と、ｎａｉｐの検定方法
US6673917B1 (en) 2000-09-28 2004-01-06 University Of Ottawa Antisense IAP nucleic acids and uses thereof
NZ546806A (en) 2002-03-27 2007-03-30 Aegera Therapeutics Inc Antisense IAP nucleobase oligomers and uses thereof
US8012944B2 (en) 2003-10-30 2011-09-06 Pharmascience Inc. Method for treating cancer using IAP antisense oligomer and chemotherapeutic agent
WO2006051757A1 (ja) * 2004-11-10 2006-05-18 Neugen Pharma, Inc 虚血性心疾患もしくは虚血性心筋症の治療剤または予防剤
PL1889065T3 (pl) 2005-05-18 2013-12-31 Novartis Ag Metody diagnostyki i leczenia chorób posiadających składnik autoimmunologiczny i/lub zapalny
KR101779370B1 (ko) 2016-06-29 2017-09-19 한국수력원자력 주식회사 방사선 조사 된 흉선 림프종 세포에서 발굴 된 세포고사 조절 유전자 및 그 검출방법

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2123406A1 (en) 1992-09-14 1994-03-31 Katia Georgopoulos Ikaros: a t cell pathway regulatory gene
CA2681922C (en) 1994-01-18 2012-05-15 The Scripps Research Institute Zinc finger protein derivatives and methods therefor
US6020127A (en) 1994-10-18 2000-02-01 The University Of Ottawa Neuronal apoptosis inhibitor protein, gene sequence and mutations causative of spinal muscular atrophy
US6156535A (en) 1995-08-04 2000-12-05 University Of Ottawa Mammalian IAP gene family, primers, probes, and detection methods
US5919912A (en) 1995-08-04 1999-07-06 University Of Ottawa Mammalian IAP antibodies and diagnostic kits
GB9601108D0 (en) 1996-01-19 1996-03-20 Univ Ottawa Neuronal apoptosis inhibitor protein (NAIP)
US6133437A (en) 1997-02-13 2000-10-17 Apoptogen, Inc. Modulation of IAPs for the treatment of proliferative diseases

Also Published As

Publication number Publication date
JPH11503620A (ja) 1999-03-30
US20020137028A1 (en) 2002-09-26
US6994957B2 (en) 2006-02-07
CA2215793A1 (en) 1997-07-24
EP1609864A3 (de) 2007-12-12
ES2245790T3 (es) 2006-01-16
WO1997026331A3 (en) 1997-10-02
GB9601108D0 (en) 1996-03-20
WO1997026331A2 (en) 1997-07-24
EP0815231B1 (de) 2005-08-03
EP1609864A2 (de) 2005-12-28
US7235372B2 (en) 2007-06-26
CA2215793C (en) 2005-07-05
JP4005135B2 (ja) 2007-11-07
DE69733861T2 (de) 2006-05-24
EP0815231A2 (de) 1998-01-07
AU1614997A (en) 1997-08-11
ATE301192T1 (de) 2005-08-15
US20060172348A1 (en) 2006-08-03
DK0815231T3 (da) 2005-12-12

Similar Documents

Publication Publication Date Title
IL130036A0 (en) Survivin a protein that inhibits cellular apoptosis and its modulation
ATE301192T1 (de) Verwendung von neuronalem apoptose- inhibitorprotein
ATE529509T1 (de) Selektion von proteinen unter verwendung von rna- protein-fusionen
DE69434614D1 (de) Cdn apoptosis modulierende proteine, sie kodierende dns und verfahren zu ihrer verwendung
DE69111596D1 (de) Verwendung von zwitterionen zur mobilisierung isoelektrisch fokussierter ampholytzonen.
EP0892048A3 (de) XAF Gene und Polypeptide und deren Verwendung zur Modulation der Apoptose
PL339860A1 (en) Methods of modulating the action of serine/threonine protein kinase by means of compounds based on 5-azaquinoxaline
WO1999019513A3 (en) Methods for detecting compounds which modulate the activity of an lpa receptor
EP1032837A4 (de) Zielsequenzen für synthetische moleküle und verfahren für deren verwendung
DE69731038D1 (de) Screening-test zur identifikation von inhibitoren des makrophagenmigrationshemmenden faktors
DE60334246D1 (de) Modulieren von immunantworten
DE69222710D1 (de) Verfahren zum Nachweis von DNS-Basen mit Verwendung von Fluoreszenz
NO20010389D0 (no) Modulering av multippel linje-kinaseproteiner
DE69606837T2 (de) Gerät zur Überprüfung der Bestimmungen von klinischen Analysen
WO2000047102A3 (en) COMPOSITIONS AND METHODS FOR MODULATING TGF-β SIGNALING
DE69807148T2 (de) Verfahren zur Hydroformylierung von Olefininen
ATE219515T1 (de) Methoden und reagenzien zur regulierung von apoptosis
DE59910237D1 (de) Verfahren zur automatischen taktfreien Erkennung von Signal-Modulationsarten
DK1007649T3 (da) Fremgangsmåder til screening for interaktioner mellem transkriptionsfaktor og coaktivator
DE69719726T2 (de) Verfahren zur Detektion von Leukämie
DE69714424D1 (de) Verwendung von kolostrum zur behandlung von darmverstopfung
ES2102776T3 (es) Inhibidores de la fosfolipasa a2.
WO2001020335A3 (en) Methods for modulating cell proliferation
DE69527559T2 (de) Verfahren zur Positionsbestimmung von Sendern
DE59504158D1 (de) Verwendung sulfierter substanzen zur fettung von leder

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee